Tempus will now work with ASCO’s CancerLinQ and Precision HealthAI to help personalize the treatment of various forms of cancer through the analysis of loads of information sourced from medical facilities regarding cancer patients, their characteristics, treatments, diagnoses, and triumphs in beating or at least stifling the disease.
CancerLinQ is its own entity, separate from parent company ASCO, that consists of in excess of 1,000,000 cancer patients’ personal, confidential information. Ever since CancerLinQ was created several years ago as a subsidiary of ASCO, the entitiy has continually been collecting information about cancer patients, their treatments, and outcomes in the face of impending, deleterious doom.
Dr. Clifford Hudis, the Chief Executive Officer of ASCO, has shared that he believes the deal between Tempus, Precision HealthAI, and CancerLinQ is practical and will bear fruit, as the pair of partners should be able to analyze CancerLinQ’s expansive warehouse of information both more efficiently and effectively than if CancerLinQ hadn’t shared such responsibilities outside of its own operations.
What We’ve Known About CancerLinQ And Its Link To Tempus
Several months ago, Eric Lefkofsky was interviewed by a journalist. Despite the interview not being primarily about Tempus’ then-upcoming deal with CancerLinQ, Mr. Lefkofsky shared that CancerLinQ’s goal was compiling huge amoutns of cancer patients’ data from healthcare providers.
Many healthcare providers, ranging from hospitals to research institutions, keep patient information of all sorts confidential, and typically don’t share it with outside organizations. However, with the security and potential for societal benefit that CancerLinQ brings to the table, countless top-tier medical providers trust CancerLinQ with their private data. Continue reading “Big News For Eric Lefkofsky’s Tempus”